KALA KALA BIO, Inc.
Distress ·
Oxford Finance says an event of default under a Material Adverse Change clause is continuing and has accelerated all obligations under the 2021 loan agreement. The notice says interest began accruing at the Default Rate, and that $29.1 million is now payable.
KALA BIO will stop developing KPI-012 and its stem cell secretome platform, cut approximately 19 employees and talk with its secured lender while it explores strategic options.
The company is selling 1,340,603 shares at $6.44 and 3,286 Series I preferred shares at $644.00. It expects the money to fund operations into the first quarter of 2026.
KALA BIO, Inc. describes itself as a biopharmaceutical company in transition, evaluating a dedicated, on-premises artificial intelligence infrastructure platform for the biotechnology industry. It historically developed therapies for rare and severe diseases of the front and back of the eye. Its lead product candidate, KPI-012, a mesenchymal stem cell secretome (MSC-S) therapy for persistent corneal epithelial defects, was discontinued after the CHASE Phase 2b clinical trial did not meet its primary endpoints. The company is evaluating strategic alternatives for its legacy MSC-S assets. It is in early-stage development of a prospective AI platform-as-a-service offering, Researgency, which it licensed from Younet AI on March 3, 2026 for deployment within biotechnology and pharmaceutical customer environments. The text states there can be no assurance that the company will successfully develop, commercialize or generate revenue from this initiative.
| Product or program | What it is | Stage |
|---|---|---|
| KPI-012 (MSC-S) | Mesenchymal stem cell secretome therapy for persistent corneal epithelial defects | development discontinued |
| Researgency AI platform | AI platform-as-a-service for biotechnology and pharmaceutical client environments | early-stage development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$27.0 million | -$38.5 million |
| Cash from operations | -$32.0 million | -$29.4 million |
| Cash and equivalents | $7.6 million | $51.2 million |
Our latest story on this, dated Dec 30, 2024: "KALA BIO agrees to $10,750,000 private placement of common and preferred stock". The story links the filing or release it is based on. Read the story.
KALA BIO, Inc. trades under the ticker KALA on NASDAQ.
KALA BIO, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0JQ2.
The SEC Central Index Key (CIK) for KALA BIO, Inc. is 1479419. Its filings are on SEC EDGAR.
19,339,786 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-19.
Our directory records KALA BIO, Inc. under United States.
Our directory classifies KALA BIO, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for KALA BIO, Inc. is US4831193010.
aibio.space lists KALA BIO, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
KALA BIO, Inc. describes itself as a biopharmaceutical company in transition, evaluating a dedicated, on-premises artificial intelligence infrastructure platform for the biotechnology industry. It historically developed therapies for rare and severe diseases of the front and back of the eye.
KPI-012 (MSC-S): Mesenchymal stem cell secretome therapy for persistent corneal epithelial defects Stage: development discontinued.
Researgency AI platform: AI platform-as-a-service for biotechnology and pharmaceutical client environments Stage: early-stage development.
KALA BIO, Inc. reported a net loss of $27.0 million for the fiscal year ended Dec 31, 2025, and used $32.0 million of cash in operations, per its annual report to the SEC.
$7.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,5.03,5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.02). Source
Reported a financing. SEC Form 8-K (Items 5.08,8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,5.02,5.03,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01). Source
Reported that a debt obligation was accelerated. SEC Form 8-K (Items 2.04). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio